Covered recipient · General Payments record
JEAN DOMERCANT
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2020–2025
$6,039.51
- Reported across 46 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $4,025.00 | 2 |
| Food and Beverage | $842.96 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $4,273.88 | 7 |
| Novo Nordisk AS | $406.19 | 6 |
| Ethicon US, LLC | $136.83 | 2 |
| Currax Pharmaceuticals LLC | $33.47 | 2 |
| INTRA-SANA LABORATORIES | $17.59 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Currax Pharmaceuticals LLC | $16.35 | 08/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1242703756 | CMS |
| Currax Pharmaceuticals LLC | $17.12 | 10/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1242703758 | CMS |
| Ethicon US, LLC | $114.29 | 07/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1173848308 | CMS |
| Ethicon US, LLC | $22.54 | 07/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1173848334 | CMS |
| Intra-Sana Laboratories | $17.59 | 04/10/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1251420604 | CMS |
| Lilly USA, LLC | $15.30 | 02/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186730867 | CMS |
| Lilly USA, LLC | $105.00 | 04/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186696649 | CMS |
| Lilly USA, LLC | $95.56 | 08/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186715935 | CMS |
| Lilly USA, LLC | $17.89 | 08/21/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186657775 | CMS |
| Lilly USA, LLC | $1,225.00 | 09/23/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1186657773 | CMS |
| Lilly USA, LLC | $2,800.00 | 09/23/2025 | Consulting Fee | Undisputed | 06/30/2026 | 1186696647 | CMS |
| Lilly USA, LLC | $15.13 | 10/22/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186715933 | CMS |
| Novo Nordisk Inc | $118.68 | 02/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188434601 | CMS |
| Novo Nordisk Inc | $20.19 | 03/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188720924 | CMS |
| Novo Nordisk Inc | $19.37 | 06/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188271811 | CMS |
| Novo Nordisk Inc | $15.41 | 08/27/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188483665 | CMS |
| Novo Nordisk Inc | $115.09 | 09/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189060801 | CMS |
| Novo Nordisk Inc | $117.45 | 11/13/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1189061097 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2020, 2021, 2023, 2024, 2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.